Skip to content

The comparison between Cydonia Oblonga and mefenamic acid on menstrual bleeding in women referred to health centers of Tabriz.

The comparison between Cydonia Oblonga and mefenamic acid on menstrual bleeding in women referred to health centers of Tabriz: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013081310324N15
Enrollment
136
Registered
2014-01-16
Start date
2013-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menorrhagia. Excessive and frequent menstruation with regular cycle

Interventions

Intervention 1: The intervention group will receive Cydonia Oblonga capsule 250 mg every 6 hours. Intervention 2: The control group will receive Mefenamic Acid Capsule 500 mg every 6 hours.
Treatment - Drugs
The intervention group will receive Cydonia Oblonga capsule 250 mg every 6 hours.
The control group will receive Mefenamic Acid Capsule 500 mg every 6 hours.

Sponsors

Vice chancellor for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women aged 18 to 45 years old; Heavy bleeding in regular menstrual cycles (at least three cycles before the study); Body mass index between 18.5-29; The absence of bleeding between menstrual cycles; Desire to participation in the study; Being literate Exclusion Criteria: Pregnancy and breast feeding; Using of Any type of drugs affecting menstrual bleeding (such as OCP, danazol, systemic and topical progestin, prostaglandin inhibitors, fibrinolytic inhibitors, gonadotropin-releasing hormone agonists); Use of the intrauterine device (IUD); Hemoglobin less than 10; Known uterine fibroids and other pathologies; Hypothyroid; Hyperthyroid; Coagulation problems and known diabetes.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The amount and intensity of menstrual bleeding. Timepoint: Before intervention, 1, 2 and 3 months after intervention. Method of measurement: Higham chart and menorrhagia questionnaire.

Secondary

MeasureTime frame
Quality of life. Timepoint: Before and three months after intervention. Method of measurement: Quality of Life Questionnaire-SF36.;Hemoglobin level. Timepoint: Before and three months after intervention. Method of measurement: Laboratory test.;Adverse events. Timepoint: 1, 2 and 3 months after intervention. Method of measurement: Checklist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRahi Pari

MSc student in Midwifery

p.rahi_1833@yahoo.com+98 28 2542 2679

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026